Literature DB >> 10901309

Efficacy of postoperative blood salvage following total hip arthroplasty in patients with and without deposited autologous units.

D Grosvenor1, V Goyal, S Goodman.   

Abstract

BACKGROUND: Patients undergoing total hip replacement routinely receive perioperative blood transfusions, increasing their risk of blood-borne disease, isoimmunization, anaphylactic reaction, and hemolytic reaction. The purpose of this retrospective, case-control study was to evaluate the effect of postoperative blood salvage on the need for allogeneic transfusion following total hip replacement.
METHODS: We reviewed the medical records of ninety consecutive patients who, during a twelve-month period, had undergone unilateral, elective total hip replacement that included use of a postoperative blood salvage device. For comparison, we reviewed the medical records of ninety consecutive patients who had undergone total hip replacement without postoperative blood salvage. Overall, 156 patients had complete medical records and were included in the study.
RESULTS: Eight (10 percent) of the patients who had been treated with a drain and seventeen (23 percent) of the patients who had been treated without a drain received allogeneic transfusions. Of the nineteen patients who had not deposited autologous blood, all six without postoperative blood salvage required allogeneic transfusion. With control for other variables in the model, regression analysis showed a significantly increased risk of allogeneic transfusion among patients who had undergone total hip replacement without postoperative blood salvage (p = 0.0028) and without having predonated autologous units (p = 0.0001).
CONCLUSIONS: Despite a limited sample size, the study results showed that postoperative blood salvage significantly reduced the risk of allogeneic transfusion among patients managed with total hip replacement, whether or not they had deposited autologous blood (p < 0.0001). With control for donated units, age, gender, preoperative hematocrit, intraoperative blood loss, and cementless technique, patients who were treated without postoperative blood salvage were approximately ten times more likely to require allogeneic transfusion than were patients who had a drain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901309     DOI: 10.2106/00004623-200007000-00006

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  6 in total

1.  Reducing the risk of allogeneic blood transfusion.

Authors:  Battista Borghi; Hanna van Oven
Journal:  CMAJ       Date:  2002-02-05       Impact factor: 8.262

2.  Transfusion of autologous blood from reinfusion systems in total knee arthroplasty.

Authors:  A Martin; A von Strempel
Journal:  Int Orthop       Date:  2006-05-31       Impact factor: 3.075

3.  Efficacy and economics of postoperative blood salvage in patients undergoing elective total hip replacement.

Authors:  Saqeb B Mirza; Jon Campion; John H Dixon; Sukhmeet S Panesar
Journal:  Ann R Coll Surg Engl       Date:  2007-11       Impact factor: 1.891

4.  Effectiveness of an autologous transfusion system following cemented and non-cemented revisions of total hip arthroplasty.

Authors:  Nael Hawi; Daniel Oliver Kendoff; Udo Hessling; Carl Haasper; Thorsten Gehrke; Mustafa Citak
Journal:  Int Orthop       Date:  2014-05-11       Impact factor: 3.075

5.  Does single use of an autologous transfusion system in TKA reduce the need for allogenic blood?: a prospective randomized trial.

Authors:  Johannes Cip; Mark Widemschek; Thomas Benesch; Roman Waibel; Arno Martin
Journal:  Clin Orthop Relat Res       Date:  2012-12-11       Impact factor: 4.176

6.  Limit allogeneic blood use with routine re-use of patient's own blood: a prospective, randomized, controlled trial in total hip surgery.

Authors:  Bregje J W Thomassen; Peter Pilot; Vanessa A B Scholtes; Josef G Grohs; Ketil Holen; Elvira Bisbe; Rudolf W Poolman
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.